샘플 요청 목록

 카트 문의
시장보고서
상품코드
1663314

출혈 컨트롤 시스템 : 시장 인사이트, 경쟁 구도, 시장 예측(2032년)

Hemorrhage Control System - Market Insights, Competitive Landscape, and Market Forecast - 2032
발행일: | 리서치사: DelveInsight | 페이지 정보: 영문 150 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

세계의 출혈 컨트롤 시스템 시장 규모는 2025-2032년의 예측 기간에 CAGR로 4.87%의 성장이 전망됩니다. 출혈 제어 시스템에 대한 수요는 주로 외상 및 부상 발생률 증가에 의해 촉진되고 있습니다. 또한 전 세계 수술 건수 증가와 만성질환의 유병률 증가는 2025-2032년의 예측 기간 중 시장 성장에 기여하는 주요 요인으로 작용할 것으로 예상됩니다.

출혈 제어 시스템 시장 역학

외상 및 부상 발생률 증가, 만성질환의 유병률 증가로 인해 출혈 제어 시스템에 대한 수요가 크게 증가하고 있습니다. "최근 'Traumatic brain injury: Epidemiology, classification, and pathophysiology'에 발표된 연구에 따르면 외상성 뇌손상(TBI)은 전 세계에서 연간 2,700만 명에서 6,900만 명에 이르는 사람들이 영향을 받는 것으로 추정되고 있습니다. TBI는 경막외출혈, 경막하출혈, 지주막하출혈 등 다양한 형태의 두개내 출혈을 유발하는 경우가 많으며, 추가적인 뇌손상 및 사망을 예방하기 위해 즉각적인 개입이 필요합니다. 두개내 출혈은 두개내압을 상승시키고 뇌손상을 악화시키기 때문에 적시에 출혈을 조절할 수 있는 솔루션이 절실히 요구되고 있습니다. 외상 관련 부상이 여전히 전 세계 이환율과 사망률의 주요 원인으로 작용함에 따라 효과적인 출혈 제어 시스템에 대한 수요는 2025-2032년의 예측 기간 중 급증할 것으로 예상됩니다.

외상 사례 외에도 만성질환의 유병률 증가로 인한 수술 건수 증가는 출혈 제어 시스템 시장의 주요 촉진요인으로, 영국 심장 재단(2024)에 따르면 전 세계에서 약 6억 2천만 명이 심장 및 순환기 질환을 앓고 있다고 합니다. 이는 약 13명 중 1명꼴로 심장 및 순환기 질환을 앓고 있습니다. GLOBOCAN(2022)에 따르면 2022년 전 세계 약 1,990만 명이 암을 앓고 있으며, 이들 중 상당수는 효율적인 출혈 관리가 필요한 침습적 출혈 환자입니다. 효율적인 출혈 관리가 필요한 침습적 수술을 받을 것으로 추정하고 있습니다. 만성질환의 유행, 항응고제의 보급, 수술 건수 증가 등의 교차점으로 인해 응급실과 수술 환경 모두에서 신뢰할 수 있는 출혈 관리 솔루션의 필요성이 증가하고 있습니다.

유망한 시장 성장 전망에도 불구하고 특정 과제가 시장 확대를 저해할 수 있습니다. 첨단 출혈 제어 제품의 높은 비용과 이러한 장비와 관련된 잠재적 부작용은 여전히 큰 제약 요인으로 작용하고 있습니다. 비용 효율적인 기술 혁신과 안전성 프로파일 개선을 통해 이러한 장벽을 극복하는 것이 수요 증가를 충분히 활용하기 위해 필수적입니다.

전반적으로 외상, 만성질환, 외과적 개입의 유병률 증가에 힘입어 출혈 제어 시스템 시장은 2025-2032년의 예측 기간 중 긍정적인 성장을 보일 것으로 예상됩니다.

북미가 전체 출혈 제어 시스템 시장을 독식할 것으로 예상됩니다.

북미는 만성질환의 유병률 증가, 외과수술 증가, 외상 및 부상 증가, 첨단 의료 인프라의 존재 등 여러 요인으로 인해 2024년 세계 출혈 제어 시스템 시장에서 가장 큰 점유율을 차지합니다. 이 지역의 제품 출시 및 규제 당국의 승인에 유리한 환경은 시장 성장에 기여할 것입니다.

PubMed Central에 발표된 2023년 연구에 따르면 미국에서는 연간 약 4,000만 건의 응급실(ED) 방문이 외상으로 인해 발생합니다. 외상은 여전히 46세 미만 사망 원인 1위이며, 이 연령대 사망자 수의 거의 절반을 차지합니다. 외상의 주요 원인인 교통사고는 즉각적인 의료 개입이 필요한 심각한 출혈로 이어지는 경우가 많습니다. 이 때문에 응급의료 현장에서는 지혈대, 압박붕대, 지혈제 등 출혈 제어 장비에 대한 수요가 증가하고 있습니다.

세계의 출혈 컨트롤 시스템 시장에 대해 조사분석했으며, 시장 규모와 예측, 과거 3년의 제품/기술개발, 시장의 주요 기업, 이용 가능한 기회 등의 정보를 제공하고 있습니다.

목차

제1장 출혈 컨트롤 시스템 시장 보고서 서론

제2장 출혈 컨트롤 시스템 시장 개요

  • 시장의 개요

제3장 경쟁 구도

제4장 규제 분석

  • 미국
  • 유럽
  • 일본
  • 중국

제5장 출혈 컨트롤 시스템 시장의 주요 요인 분석

  • 출혈 컨트롤 시장 촉진요인
  • 출혈 컨트롤 시장 억제요인과 과제
  • 출혈 컨트롤 시장의 기회

제6장 출혈 컨트롤 시스템 시장의 Porter's Five Forces 분석

제7장 출혈 컨트롤 시스템 시장 평가

  • 제품별
    • 출혈 컨트롤 디바이스
    • 지혈제
    • 기타
  • 용도별
    • 심혈관수술
    • 정형외과수술
    • 일반 외과수술
  • 최종사용자별
    • 병원, 진료소
    • 외래 수술 센터
  • 지역
    • 북미
    • 유럽
    • 아시아태평양
    • 기타 지역

제8장 출혈 컨트롤 시스템 시장의 기업과 제품 개요

  • Medtronic
  • MED Alliance Group, Inc.
  • Organon
  • EndoClot Plus, Inc.
  • Aero Healthcare AU Pty Ltd.
  • Stryker
  • Safeguard
  • Zimmer Biomet
  • Sam Medical
  • RevMedx
  • BD
  • Baxter
  • Johnson & Johnson
  • Hemostasis, LLC.
  • Pfizer
  • Starch Medical, Inc.
  • Teleflex Incorporated
  • Arch Therapeutics, Inc.
  • Dilon Technologies
  • Medtrade Products Ltd.

제9장 KOL의 견해

제10장 프로젝트 어프로치

제11장 DelveInsight 소개

제12장 면책사항, 문의

KSA 25.03.11

Hemorrhage Control System Market by Product (Hemorrhage Control Devices, Hemostatic Agents, and Others), Application (Cardiovascular Surgery, General Surgery, Orthopedic Surgery, and Others), End-User (Hospitals and Clinics, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the rising incidence of trauma and injuries and increasing surgical procedures across the globe.

The hemorrhage control system market is estimated to grow at a CAGR of 4.87% during the forecast period from 2025 to 2032. The demand for hemorrhage control systems is primarily driven by the rising incidence of trauma and injuries. Additionally, the growing number of surgical procedures worldwide and the increasing prevalence of chronic diseases are key factors contributing to the market's growth during the forecast period of 2025 to 2032.

HEMORRHAGE CONTROL SYSTEM MARKET DYNAMICS:

The demand for hemorrhage control systems is witnessing significant growth, driven by the rising incidence of trauma, and injuries, and the increasing prevalence of chronic diseases. According to a recent study published in the journal Traumatic Brain Injury: Epidemiology, Classification, and Pathophysiology, traumatic brain injury (TBI) is a major global health concern, affecting an estimated 27 to 69 million people annually. TBI frequently results in various forms of intracranial hemorrhage, including epidural, subdural, and subarachnoid bleeding, which require immediate intervention to prevent further brain damage or death. Intracranial bleeding elevates intracranial pressure, exacerbating brain injury and underscoring the critical need for timely hemorrhage control solutions. As trauma-related injuries remain a significant contributor to global morbidity and mortality, the demand for effective hemorrhage control systems is expected to surge during the forecast period from 2025 to 2032.

Beyond trauma cases, the growing number of surgical procedures driven by the increasing prevalence of chronic diseases is another key factor propelling the hemorrhage control system market. According to the British Heart Foundation (2024), approximately 620 million people worldwide live with heart and circulatory diseases, equating to roughly 1 in 13 individuals. These patients, often on anticoagulant or antiplatelet therapies to mitigate clotting risks, face a heightened likelihood of excessive bleeding during trauma, surgery, or spontaneous hemorrhages. Similarly, cancer prevalence further drives surgical interventions; GLOBOCAN (2022) estimated that approximately 19.9 million people globally were living with cancer in 2022, many of whom undergo invasive procedures requiring efficient hemorrhage management. The intersection of chronic disease prevalence, widespread use of blood-thinning medications, and increasing surgical volumes underscores the growing need for reliable hemorrhage control solutions in both emergency and operative settings.

Despite the market's promising growth prospects, certain challenges may restrain expansion. The high cost of advanced hemorrhage control products and potential side effects associated with these devices remain notable constraints. Addressing these barriers through cost-effective innovations and improved safety profiles will be essential to fully capitalize on the increasing demand.

Overall, fueled by the rising prevalence of trauma, chronic diseases, and surgical interventions, the hemorrhage control system market is poised for positive growth during the forecast period of 2025 to 2032.

HEMORRHAGE CONTROL SYSTEM MARKET SEGMENT ANALYSIS:

Hemorrhage Control System Market by Product (Hemorrhage Control Devices, Hemostatic Agents, and Others), Application (Cardiovascular Surgery, General Surgery, Orthopedic Surgery, and Others), End-User (Hospitals and Clinics, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the product type segment of the hemorrhage control system market, the hemorrhage control devices category is projected to secure a significant revenue share in 2024. This growth is attributed to the wide range of advantages and critical applications these devices offer in emergency and surgical settings. Designed to rapidly stop or minimize blood loss, these devices play a vital role in preventing shock and fatal complications resulting from hemorrhage.

Devices such as tourniquets and hemostatic dressings can be applied within seconds, significantly improving survival rates in trauma cases by controlling bleeding during the critical "golden hour" following an injury. Early intervention with these devices stabilizes patients until professional medical care becomes available, increasing the likelihood of positive outcomes. Furthermore, advancements in technology have led to the development of specialized devices like junctional tourniquets, which effectively manage bleeding in challenging anatomical regions such as the groin and armpit areas where traditional methods may prove inadequate.

The increasing adoption of these devices in both civilian and military settings, coupled with their ease of use and effectiveness in pre-hospital environments, is further fueling demand. Additionally, growing awareness of the importance of immediate hemorrhage control and the implementation of emergency response protocols across various sectors are driving market expansion.

Therefore, owing to these factors, the hemorrhage control system devices category is expected to register significant growth, thereby propelling the overall hemorrhage control system market during the forecast period.

NORTH AMERICA IS EXPECTED TO DOMINATE THE OVERALL HEMORRHAGE CONTROL SYSTEM MARKET:

North America is projected to account for the largest share of the global hemorrhage control system market in 2024, driven by several key factors, including the rising prevalence of chronic diseases, an increasing number of surgical procedures, a high incidence of trauma and injuries, and the presence of advanced healthcare infrastructure. The region's favorable environment for product launches and regulatory approvals further contributes to market growth.

According to a 2023 study published in PubMed Central, traumatic injuries account for approximately 40 million emergency department (ED) visits annually in the United States. Trauma remains the leading cause of mortality among individuals under 46 years of age, responsible for nearly half of all fatalities in this age group. Road traffic accidents, a major cause of trauma, frequently lead to severe bleeding that necessitates immediate medical intervention. This has heightened the demand for hemorrhage control devices such as tourniquets, pressure bandages, and hemostatic agents in emergency care settings.

The rising burden of chronic diseases in North America further drives the need for surgical interventions requiring effective hemorrhage management. Patients with cardiovascular conditions, cancer, or those on anticoagulant therapies are at increased risk of bleeding complications during surgeries or in emergencies, amplifying the demand for reliable hemorrhage control solutions.

Additionally, product innovations and regulatory approvals in the region play a significant role in market expansion. For example, in November 2023, Ethicon, a Johnson & Johnson MedTech company, received approval for ETHIZIA(TM), an adjunctive hemostat solution clinically proven to achieve sustained hemostasis in difficult-to-control bleeding situations. Such advancements highlight the region's robust innovation ecosystem and commitment to improving patient outcomes.

Therefore, the combination of a high trauma burden, increasing surgical volumes, a supportive regulatory environment, and continuous product innovation is expected to drive substantial growth in the hemorrhage control system market in North America during the forecast period of 2025 to 2032.

HEMORRHAGE CONTROL SYSTEM MARKET KEY PLAYERS:

Some of the key market players operating in the hemorrhage control system market include Medtronic, MED Alliance Group, Inc., Organon, EndoClot Plus, Inc., Aero Healthcare AU Pty Ltd., Stryker, Safeguard, Zimmer Biomet, Sam Medical, RevMedx, BD, Baxter, Johnson & Johnson, Hemostasis, LLC., Pfizer, Starch Medical, Inc., Teleflex Incorporated, Arch Therapeutics, Inc., Dilon Technologies, Medtrade Products Ltd., and others.

RECENT DEVELOPMENTAL ACTIVITIES IN THE HEMORRHAGE CONTROL SYSTEM MARKET:

  • In October 2021, Organon announced that the U.S. Food and Drug Administration (FDA) had granted Special 510(k) clearance for technological enhancements to the Jada(R) System. The device is designed to control and treat abnormal postpartum uterine bleeding or hemorrhage when conservative management is appropriate, offering an advanced solution for postpartum hemorrhage care.
  • In February 2021, EndoClot Plus, Inc. received FDA approval for its EndoClot Polysaccharide Hemostatic System (PHS). This innovative system is intended to effectively control bleeding during gastrointestinal (GI) procedures, providing a rapid, safe, and efficient solution for hemostasis in endoscopic interventions.

KEY TAKEAWAYS FROM THE HEMORRHAGE CONTROL SYSTEM MARKET REPORT STUDY

  • Market size analysis for current hemorrhage control system market size (2024), and market forecast for 8 years (2025 to 2032)
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
  • Key companies dominating the hemorrhage control system market.
  • Various opportunities available for the other competitors in the hemorrhage control system market space.
  • What are the top-performing segments in 2024? How these segments will perform in 2032?
  • Which are the top-performing regions and countries in the current hemorrhage control system market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for hemorrhage control system market growth in the coming future?

TARGET AUDIENCE WHO CAN BE BENEFITED FROM THIS HEMORRHAGE CONTROL SYSTEM MARKET REPORT STUDY

  • Hemorrhage control product providers
  • Research organizations and consulting companies
  • Hemorrhage control system - related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and traders dealing in hemorrhage control system
  • Various end-users who want to know more about the hemorrhage control system market and the latest technological developments in the hemorrhage control system market.

FREQUENTLY ASKED QUESTIONS FOR THE HEMORRHAGE CONTROL SYSTEM MARKET:

1. What is meant by a hemorrhage control system?

  • Hemorrhage control refers to the medical techniques, procedures, and devices used to stop or reduce excessive bleeding (hemorrhage), either externally (on the body surface) or internally (within the body or organs). Hemorrhage can occur due to trauma, surgery, medical conditions, or other factors, and if left uncontrolled, it can lead to shock, organ failure, or death.

2. What is the market for a hemorrhage control system?

  • The hemorrhage control system market is estimated to grow at a CAGR of 4.87% during the forecast period from 2025 to 2032.

3. What are the drivers for the global hemorrhage control system market?

  • The demand for hemorrhage control systems is primarily being boosted by the rising incidence of trauma and injuries. Additionally, increasing surgical procedures across the globe and increasing prevalence of chronic diseases are some of the factors that are contributing to the growth of the hemorrhage control system market during the forecast period from 2025 to 2032.

4. Who are the key players operating in the global hemorrhage control system market?

  • Some of the key market players operating in the Hemorrhage Control market include Medtronic, MED Alliance Group, Inc., Organon, EndoClot Plus, Inc., Aero Healthcare AU Pty Ltd., Stryker, Safeguard, Zimmer Biomet, Sam Medical, RevMedx, BD, Baxter, Johnson & Johnson, Hemostasis, LLC., Pfizer, Starch Medical, Inc., Teleflex Incorporated, Arch Therapeutics, Inc., Dilon Technologies, Medtrade Products Ltd., and others.

5. Which region has the highest share in the global hemorrhage control system market?

  • North America is expected to dominate the overall hemorrhage control system market during the forecast period, 2025 to 2032. This is due to the rising prevalence of chronic disease in the region, leading to an increasing number of surgical procedures. Additionally, the increasing incidence of trauma and injury, the presence of sophisticated healthcare infrastructure, and the presence of a viable market in terms of product launch and approval are some of the key factors driving the growth of the hemorrhage control system market in North America.

Table of Contents

1. Hemorrhage Control System Market Report Introduction

  • 1.1. Scope of the Study
  • 1.2. Market Segmentation
  • 1.3. Market Assumption

2. Hemorrhage Control System Market Executive Summary

  • 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

  • 4.1. The United States
  • 4.2. Europe
  • 4.3. Japan
  • 4.4. China

5. Hemorrhage Control System Market Key Factors Analysis

  • 5.1. Hemorrhage Control Market Drivers
    • 5.1.1. Rising incidence of Trauma and Injuries
    • 5.1.2. Increasing surgical procedures across the globe
  • 5.2. Hemorrhage Control Market Restraints and Challenges
    • 5.2.1. High cost of advanced hemorrhage products
    • 5.2.2. Risk of side-effects associated with these devices
  • 5.3. Hemorrhage Control Market Opportunities
    • 5.3.1. Integration of nanotechnology in the development of hemostatic agents

6. Hemorrhage Control System Market Porter's Five Forces Analysis

  • 6.1. Bargaining Power of Suppliers
  • 6.2. Bargaining Power of Consumers
  • 6.3. Threat of New Entrants
  • 6.4. Threat of Substitutes
  • 6.5. Competitive Rivalry

7. Hemorrhage Control System Market Assessment

  • 7.1. By Product
    • 7.1.1. Hemorrhage Control Devices
    • 7.1.2. Hemostatic Agents
    • 7.1.3. Others
  • 7.2. By Application
    • 7.2.1. Cardiovascular Surgery
    • 7.2.2. Orthopedic Surgery
    • 7.2.3. General Surgery
    • 7.2.4. Others
  • 7.3. By End-User
    • 7.3.1. Hospitals and Clinics
    • 7.3.2. Ambulatory Surgical Centers
    • 7.3.3. Others
  • 7.4. By Geography
    • 7.4.1. North America
      • 7.4.1.1. United States Hemorrhage Control System Market Size in USD million (2022-2032)
      • 7.4.1.2. Canada Hemorrhage Control System Market Size in USD million (2022-2032)
      • 7.4.1.3. Mexico Hemorrhage Control System Market Size in USD million (2022-2032)
    • 7.4.2. Europe
      • 7.4.2.1. France Hemorrhage Control System Market Size in USD million (2022-2032)
      • 7.4.2.2. Germany Hemorrhage Control System Market Size in USD million (2022-2032)
      • 7.4.2.3. United Kingdom Hemorrhage Control System Market Size in USD million (2022-2032)
      • 7.4.2.4. Italy Hemorrhage Control System Market Size in USD million (2022-2032)
      • 7.4.2.5. Spain Hemorrhage Control System Market Size in USD million (2022-2032)
      • 7.4.2.6. Rest of Europe Hemorrhage Control System Market Size in USD million (2022-2032)
    • 7.4.3. Asia-Pacific
      • 7.4.3.1. China Hemorrhage Control System Market Size in USD million (2022-2032)
      • 7.4.3.2. Japan Hemorrhage Control System Market Size in USD million (2022-2032)
      • 7.4.3.3. India Hemorrhage Control System Market Size in USD million (2022-2032)
      • 7.4.3.4. Australia Hemorrhage Control System Market Size in USD million (2022-2032)
      • 7.4.3.5. South Korea Hemorrhage Control System Market Size in USD million (2022-2032)
      • 7.4.3.6. Rest of Asia-Pacific Hemorrhage Control System Market Size in USD million (2022-2032)
    • 7.4.4. Rest of the World (RoW)
      • 7.4.4.1. Middle East Hemorrhage Control System Market Size in USD million (2022-2032)
      • 7.4.4.2. Africa Hemorrhage Control System Market Size in USD million (2022-2032)
      • 7.4.4.3. South America Hemorrhage Control System Market Size in USD million (2022-2032)

8. Hemorrhage Control System Market Company and Product Profiles

  • 8.1. Medtronic
    • 8.1.1. Company Overview
    • 8.1.2. Company Snapshot
    • 8.1.3. Financial Overview
    • 8.1.4. Product Listing
    • 8.1.5. Entropy
  • 8.2. MED Alliance Group, Inc.
    • 8.2.1. Company Overview
    • 8.2.2. Company Snapshot
    • 8.2.3. Financial Overview
    • 8.2.4. Product Listing
    • 8.2.5. Entropy
  • 8.3. Organon
    • 8.3.1. Company Overview
    • 8.3.2. Company Snapshot
    • 8.3.3. Financial Overview
    • 8.3.4. Product Listing
    • 8.3.5. Entropy
  • 8.4. EndoClot Plus, Inc.
    • 8.4.1. Company Overview
    • 8.4.2. Company Snapshot
    • 8.4.3. Financial Overview
    • 8.4.4. Product Listing
    • 8.4.5. Entropy
  • 8.5. Aero Healthcare AU Pty Ltd.
    • 8.5.1. Company Overview
    • 8.5.2. Company Snapshot
    • 8.5.3. Financial Overview
    • 8.5.4. Product Listing
    • 8.5.5. Entropy
  • 8.6. Stryker
    • 8.6.1. Company Overview
    • 8.6.2. Company Snapshot
    • 8.6.3. Financial Overview
    • 8.6.4. Product Listing
    • 8.6.5. Entropy
  • 8.7. Safeguard
    • 8.7.1. Company Overview
    • 8.7.2. Company Snapshot
    • 8.7.3. Financial Overview
    • 8.7.4. Product Listing
    • 8.7.5. Entropy
  • 8.8. Zimmer Biomet
    • 8.8.1. Company Overview
    • 8.8.2. Company Snapshot
    • 8.8.3. Financial Overview
    • 8.8.4. Product Listing
    • 8.8.5. Entropy
  • 8.9. Sam Medical
    • 8.9.1. Company Overview
    • 8.9.2. Company Snapshot
    • 8.9.3. Financial Overview
    • 8.9.4. Product Listing
    • 8.9.5. Entropy
  • 8.10. RevMedx
    • 8.10.1. Company Overview
    • 8.10.2. Company Snapshot
    • 8.10.3. Financial Overview
    • 8.10.4. Product Listing
    • 8.10.5. Entropy
  • 8.11. BD
    • 8.11.1. Company Overview
    • 8.11.2. Company Snapshot
    • 8.11.3. Financial Overview
    • 8.11.4. Product Listing
    • 8.11.5. Entropy
  • 8.12. Baxter
    • 8.12.1. Company Overview
    • 8.12.2. Company Snapshot
    • 8.12.3. Financial Overview
    • 8.12.4. Product Listing
    • 8.12.5. Entropy
  • 8.13. Johnson & Johnson
    • 8.13.1. Company Overview
    • 8.13.2. Company Snapshot
    • 8.13.3. Financial Overview
    • 8.13.4. Product Listing
    • 8.13.5. Entropy
  • 8.14. Hemostasis, LLC.
    • 8.14.1. Company Overview
    • 8.14.2. Company Snapshot
    • 8.14.3. Financial Overview
    • 8.14.4. Product Listing
    • 8.14.5. Entropy
  • 8.15. Pfizer
    • 8.15.1. Company Overview
    • 8.15.2. Company Snapshot
    • 8.15.3. Financial Overview
    • 8.15.4. Product Listing
    • 8.15.5. Entropy
  • 8.16. Starch Medical, Inc.
    • 8.16.1. Company Overview
    • 8.16.2. Company Snapshot
    • 8.16.3. Financial Overview
    • 8.16.4. Product Listing
    • 8.16.5. Entropy
  • 8.17. Teleflex Incorporated
    • 8.17.1. Company Overview
    • 8.17.2. Company Snapshot
    • 8.17.3. Financial Overview
    • 8.17.4. Product Listing
    • 8.17.5. Entropy
  • 8.18. Arch Therapeutics, Inc.
    • 8.18.1. Company Overview
    • 8.18.2. Company Snapshot
    • 8.18.3. Financial Overview
    • 8.18.4. Product Listing
    • 8.18.5. Entropy
  • 8.19. Dilon Technologies
    • 8.19.1. Company Overview
    • 8.19.2. Company Snapshot
    • 8.19.3. Financial Overview
    • 8.19.4. Product Listing
    • 8.19.5. Entropy
  • 8.20. Medtrade Products Ltd.
    • 8.20.1. Company Overview
    • 8.20.2. Company Snapshot
    • 8.20.3. Financial Overview
    • 8.20.4. Product Listing
    • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제